Case Histories
Articles in this series discuss the discovery and development of particular drugs or drug classes. Written by those closely involved in the discovery process, these aim to provide insights that will aid in future drug discovery programs.
Index
2008
May 2008 Vol 7 No 5
Aliskiren: the first renin inhibitor for clinical treatment
Chris Jensen, Peter Herold & Hans Rudolf Brunner
p399 | doi:10.1038/nrd2550
2007
December 2007 Vol 6 No 12
The war against influenza: discovery and development of sialidase inhibitors
Mark von Itzstein
p967 | doi:10.1038/nrd2400
September 2007 Vol 6 No 9
Molecular basis for sunitinib efficacy and future clinical development
Sandrine Faivre, George Demetri, William Sargent & Eric Raymond
p734 | doi:10.1038/nrd2380
2006
February 2006 Vol 5 No 2
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Eugene W. M. Ng, David T. Shima, Perry Calias, Emmett T. Cunningham, Jr., David R. Guyer and Anthony P. Adamis
p123 | doi:10.1038/nrd1955
2005
September 2005 Vol 4 No 9
The discovery of fluoxetine hydrochloride (Prozac)
David T. Wong, Kenneth W. Perry & Frank P. Bymaster
p764 | doi:10.1038/nrd1821
2004
August 2004 Vol 3 No 8
A new oral anticoagulant: the 50-year challenge
David Gustafsson, Ruth Bylund, Thomas Antonsson, Ingemar Nilsson, Jan-Erik Nystr�m, Ulf Eriksson, Ulf Bredberg & Ann-Catrine Teger-Nilsson
p649 | doi:10.1038/nrd1466
May 2004 Vol 3 No 5
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Napoleone Ferrara, Kenneth J. Hillan, Hans-Peter Gerber & William Novotny
p391 | doi:10.1038/nrd1381
March 2004 Vol 3 No 3
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes
Tom Matthews, Miklos Salgo, Michael Greenberg, Jain Chung, Ralph DeMasi & Dani Bolognesi
p215 | doi:10.1038/nrd1331
2003
July 2003 Vol 2 No 7
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
Jonathan A. Tobert
p517 | doi:10.1038/nrd1112
March 2003 Vol 2 No 3
The development of COX2 inhibitors
Rod J. Flower
p179 | doi:10.1038/nrd1034
Tamoxifen: a most unlikely pioneering medicine
V. Craig Jordan
p205 | doi:10.1038/nrd1031
February 2003 Vol 2 No 2
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole
Lars Olbe, Enar Carlsson & Per Lindberg
p132 | doi:10.1038/nrd1010
2002
July 2002 Vol 1 No 7
Glivec (STI571, Imatinib), a rationally developed, targeted anticancer drug
Renaud Capdeville, Elisabeth Buchdunger, Juerg Zimmermann & Alex Matter
p493 | doi:10.1038/nrd839
